TMB-H

News alerts, weekly reports and conference planners

Related biomarkers:

Others

‹

›

Related tests:

FoundationOne® CDx (106)

TMB-H	Soft Tissue Sarcoma	TMB-H	Soft Tissue Sarcoma	nivolumab Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) nivolumab Sensitive : A2 NCCN - 2wk	nivolumab Sensitive: A2 - Guideline NCCN - 2 weeks nivolumab Sensitive : A2 NCCN - 2 weeks - (New A2)
TMB-H	Soft Tissue Sarcoma	TMB-H	Soft Tissue Sarcoma	nivolumab + ipilimumab Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) nivolumab + ipilimumab Sensitive : A2 NCCN - 2wk	nivolumab + ipilimumab Sensitive: A2 - Guideline NCCN - 2 weeks nivolumab + ipilimumab Sensitive : A2 NCCN - 2 weeks - (New A2)
TMB-H	Soft Tissue Sarcoma	TMB-H	Soft Tissue Sarcoma	pembrolizumab + ipilimumab Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) pembrolizumab + ipilimumab Sensitive : A2 NCCN - 2wk	pembrolizumab + ipilimumab Sensitive: A2 - Guideline NCCN - 2 weeks pembrolizumab + ipilimumab Sensitive : A2 NCCN - 2 weeks - (New A2)
TMB-H	Ovarian Cancer	TMB-H	Ovarian Cancer	ABT-888 Sensitive: B - Late Trials AACR 2023 - 2 weeks (New B) ABT-888 Sensitive : B AACR 2023 - 2wk	ABT-888 Sensitive: B - Late Trials AACR 2023 - 2 weeks ABT-888 Sensitive : B AACR 2023 - 2 weeks - (New B)
TMB-H	Gastric Cancer	TMB-H	Gastric Cancer	pembrolizumab Sensitive: A2 - Guideline AACR 2023 - 2 weeks (New C3) pembrolizumab Sensitive : A2 AACR 2023 - 2wk	pembrolizumab Sensitive: A2 - Guideline AACR 2023 - 2 weeks pembrolizumab Sensitive : A2 AACR 2023 - 2 weeks - (New C3)
TMB-H	Soft Tissue Sarcoma	TMB-H	Soft Tissue Sarcoma	pembrolizumab Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) pembrolizumab Sensitive : A2 NCCN - 2wk	pembrolizumab Sensitive: A2 - Guideline NCCN - 2 weeks pembrolizumab Sensitive : A2 NCCN - 2 weeks - (New A2)
TMB-H	Non Small Cell Lung Cancer	TMB-H	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C1 - Off-label AACR 2023 - 2 weeks (New D) pembrolizumab Sensitive : C1 AACR 2023 - 2wk	pembrolizumab Sensitive: C1 - Off-label AACR 2023 - 2 weeks pembrolizumab Sensitive : C1 AACR 2023 - 2 weeks - (New D)
TMB-H	Gastric Cancer	TMB-H	Gastric Cancer	nivolumab Sensitive: C3 – Early Trials AACR 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 AACR 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials AACR 2023 - 2 weeks nivolumab Sensitive : C3 AACR 2023 - 2 weeks - (New C3)
TMB-H	Non Small Cell Lung Cancer	TMB-H	Non Small Cell Lung Cancer	dostarlimab Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) dostarlimab Sensitive : D AACR 2023 - 2wk	dostarlimab Sensitive: D – Preclinical AACR 2023 - 2 weeks dostarlimab Sensitive : D AACR 2023 - 2 weeks - (New D)
TMB-H	Biliary Tract Cancer	TMB-H	Biliary Tract Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) nivolumab + ipilimumab Sensitive : A2 NCCN - 3wk	nivolumab + ipilimumab Sensitive: A2 - Guideline NCCN - 3 weeks nivolumab + ipilimumab Sensitive : A2 NCCN - 3 weeks - (New A2)
TMB-H	Solid Tumor	TMB-H	Solid Tumor	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
TMB-H	Peritoneal Cancer	TMB-H	Peritoneal Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Testicular Seminoma	TMB-H	Testicular Seminoma	TIP Sensitive: A2 - Guideline TIP Sensitive : A2	TIP Sensitive: A2 - Guideline TIP Sensitive : A2
TMB-H	Sarcoma	TMB-H	Sarcoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Thyroid Gland Hurthle Cell Carcinoma	TMB-H	Thyroid Gland Hurthle Cell Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Chordoma	TMB-H	Chordoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Germ Cell Tumors	TMB-H	Germ Cell Tumors	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Thyroid Gland Follicular Carcinoma	TMB-H	Thyroid Gland Follicular Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Thyroid Gland Medullary Carcinoma	TMB-H	Thyroid Gland Medullary Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Endometrial Cancer	TMB-H	Endometrial Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Cervical Cancer	TMB-H	Cervical Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Thyroid Gland Papillary Carcinoma	TMB-H	Thyroid Gland Papillary Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Non Small Cell Lung Cancer	TMB-H	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
TMB-H	Breast Cancer	TMB-H	Breast Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Melanoma	TMB-H	Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
TMB-H	Solid Tumor	TMB-H	Solid Tumor	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
TMB-H	Ewing Sarcoma	TMB-H	Ewing Sarcoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Osteosarcoma	TMB-H	Osteosarcoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Penile Cancer	TMB-H	Penile Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Thyroid Gland Anaplastic Carcinoma	TMB-H	Thyroid Gland Anaplastic Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Gastroesophageal Junction Adenocarcinoma	TMB-H	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Esophageal Cancer	TMB-H	Esophageal Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Pancreatic Adenocarcinoma	TMB-H	Pancreatic Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Ovarian Cancer	TMB-H	Ovarian Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Fallopian Tube Cancer	TMB-H	Fallopian Tube Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Neuroendocrine Tumor	TMB-H	Neuroendocrine Tumor	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Testicular Cancer	TMB-H	Testicular Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Vulvar Cancer	TMB-H	Vulvar Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Prostate Cancer	TMB-H	Prostate Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Nasopharyngeal Carcinoma	TMB-H	Nasopharyngeal Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Biliary Tract Cancer	TMB-H	Biliary Tract Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Head and Neck Cancer	TMB-H	Head and Neck Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2

TMB-H

Associations